You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):目前用於治療成人單純性甲型流感的一類創新藥物昂拉地韋片已結束III期臨牀試驗入組
格隆匯 09-20 16:09

格隆匯9月20日丨眾生藥業(002317.SZ)在9月19日投資者關係活動上表示,目前用於治療成人單純性甲型流感的一類創新藥物昂拉地韋片已結束III期臨牀試驗入組,並收到頂線數據初步統計分析結果:該試驗獲得了積極結果,本研究已達到方案預設的主要療效終點指標,且安全性良好。公司將在全國主要研究者、總負責人的帶領下,繼續與各合作單位保持密切合作,積極做好與國家藥品監管部門的溝通與交流,推進本品的研發與註冊進程。公司將結合項目整體研發進度和研發策略,並參考相關指導原則,適時推進ZSP1273顆粒以及兒童適應症相關臨牀研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account